Surgical Science Q2 2024: Sales in line, soft profitability due to revenue mix - Redeye

Redeye provides its initial take on Surgical Science’s Q2 2024 report, which featured a notable sequential recovery after the company’s weak Q1. We judge that positives from the report include sales aligning with our expectations. Notable negatives include softer-than-expected profitability, mainly resulting from revenue mix leading to lower-than-expected gross margins. We expect stronger growth and profitability in H2 2024e.

Länk till analysen i sin helhet: https://www.redeye.se/research/1032763/surgical-science-q2-2024-sales-in-line-soft-profitability-due-to-revenue-mix?utm_source=finwire&utm_medium=RSS